Thomas Graham, Alan, Irving Kahns
Kahn Brothers Group
Kahn Brothers Group Portfolio 13F
Kahn Brothers Group Holdings Activity
- Portfolio value:
- $742.71M≈ (-$45M≈)
- Previous value:
- $787.55M≈
- # of changes:
- 34
- New positions:
- 0
- Reported for:
- 30 Jun 2022 (Q2)
- Latest filing date:
- 10 Aug 2022
Kahn Brothers Group has disclosed a total of 34 changes to the portfolio in the (2022 Q2) SEC report(s): increased the number of shares of 22, decreased the number of shares of 11 and completely sold out 1 position(s).
What stocks did Kahn Brothers Group buy in 2022 Q2?
During 2022 Q2 Kahn Brothers Group has bought 22 securities out of which top 5 purchases (by % change to portfolio) were (BMY) Bristol-Myers Squibb Company (added shares +0.34%), (MRK) Merck & Company Inc (added shares +0.65%), (GSK) GlaxoSmithKline PLC ADR (added shares +0.32%), (MBI) MBIA Inc (added shares +0.15%) and (PFE) Pfizer Inc (added shares +0.53%).
What did Kahn Brothers Group invest in during 2022 Q2?
In the 2022 Q2 report(s) the following changes have been made to the top investments: (PTEN) Patterson-UTI Energy Inc (reduced shares -17.34%), (AGO) ASSURED GUARANTY LTD (reduced shares -1.40%), (BMY) Bristol-Myers Squibb Company (added shares +0.34%), (MRK) Merck & Company Inc (added shares +0.65%) and (BP) BP PLC-SPONS ADR (reduced shares -0.39%).
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
* Current price: this can be a delayed price and may not reflect the real-time market value, however it is too close.
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* Held since / Held for: calculated since the latest "new buy" position. If the security was previously exited and re-entered, only the most recent holding period is counted.